The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging
<p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiat...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-05-01
|
Series: | European Journal of Medical Research |
Subjects: | |
Online Access: | http://www.eurjmedres.com/content/17/1/10 |
id |
doaj-48d78004090548008d237a2b7799b111 |
---|---|
record_format |
Article |
spelling |
doaj-48d78004090548008d237a2b7799b1112020-11-25T00:13:46ZengBMCEuropean Journal of Medical Research2047-783X2012-05-011711010.1186/2047-783X-17-10The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical stagingSchauer Matthias CStoecklein Nikolas HTheisen JoergKröpil FerideBaldus StephanHoelscher ArnulfFeith MarkusBölke EdwinMatuschek ChristianeBudach WilfriedKnoefel Wolfram<p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiation, overexpression of Eph B3 in cancer cell lines inhibits growth and induces functional changes with decreased mesenchymal and increased epithelial markers. In order to study this tumor suppressor activity of Eph B3 in esophageal adenocarcinoma we analyzed the simultaneous expression of Eph B3 and E-cadherin in both the healthy esophagus and in Barrett’s carcinoma.</p> <p>Methods</p> <p>Simultaneous expression of Eph B3 and E-cadherin was investigated in samples from 141 patients with Barrett’s carcinoma and from 20 healthy esophagi using immunhistology and quantitative PCR. Results from healthy squamous epithelium, Barrett’s metaplasia and staging-specific esophageal adenocarcinoma were correlated.</p> <p>Results</p> <p>A significantly reduced E-cadherin mRNA expression could be detected in adenocarcinoma compared to dysplasia. The immunhistological activity of E-cadherin and Eph B3 was reduced in adenocarcinoma compared to dysplasia or healthy esophageal mucosa. The intracellular E-cadherin distribution changed significantly from the cytoplasm to the membrane, when the Eph receptor was simultaneously expressed. Simultaneous expression of E-cadherin and Eph B3 showed a significant inverse correlation to tumor stage.</p> <p>Conclusions</p> <p>We present novel evidence of the tumor suppressor activity of Eph B3 in esophageal adenocarcinoma possibly due to the impact on redistribution of cellular E-cadherin to the membrane. Our results suggest that this effect might play a role in the dysplasia-adenocarcinoma sequence, the infiltrative growth pattern and the development of lymph node metastases.</p> http://www.eurjmedres.com/content/17/1/10E-cadherinEphrin B3 receptorEsophageal adenocarcinomaBarrett’s metaplasia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Schauer Matthias C Stoecklein Nikolas H Theisen Joerg Kröpil Feride Baldus Stephan Hoelscher Arnulf Feith Markus Bölke Edwin Matuschek Christiane Budach Wilfried Knoefel Wolfram |
spellingShingle |
Schauer Matthias C Stoecklein Nikolas H Theisen Joerg Kröpil Feride Baldus Stephan Hoelscher Arnulf Feith Markus Bölke Edwin Matuschek Christiane Budach Wilfried Knoefel Wolfram The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging European Journal of Medical Research E-cadherin Ephrin B3 receptor Esophageal adenocarcinoma Barrett’s metaplasia |
author_facet |
Schauer Matthias C Stoecklein Nikolas H Theisen Joerg Kröpil Feride Baldus Stephan Hoelscher Arnulf Feith Markus Bölke Edwin Matuschek Christiane Budach Wilfried Knoefel Wolfram |
author_sort |
Schauer Matthias C |
title |
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging |
title_short |
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging |
title_full |
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging |
title_fullStr |
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging |
title_full_unstemmed |
The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett`s adenocarcinoma is associated with favorable clinical staging |
title_sort |
simultaneous expression of both ephrin b3 receptor and e-cadherin in barrett`s adenocarcinoma is associated with favorable clinical staging |
publisher |
BMC |
series |
European Journal of Medical Research |
issn |
2047-783X |
publishDate |
2012-05-01 |
description |
<p>Abstract</p> <p>Background</p> <p>In intestinal epithelium, tyrosine kinase receptor Ephrin B3 (Eph B3) maintains the architecture of the crypt-villus axis by repulsive interaction with its ligand ephrin-B1. While loss of Eph B3 is linked to colorectal cancer initiation, overexpression of Eph B3 in cancer cell lines inhibits growth and induces functional changes with decreased mesenchymal and increased epithelial markers. In order to study this tumor suppressor activity of Eph B3 in esophageal adenocarcinoma we analyzed the simultaneous expression of Eph B3 and E-cadherin in both the healthy esophagus and in Barrett’s carcinoma.</p> <p>Methods</p> <p>Simultaneous expression of Eph B3 and E-cadherin was investigated in samples from 141 patients with Barrett’s carcinoma and from 20 healthy esophagi using immunhistology and quantitative PCR. Results from healthy squamous epithelium, Barrett’s metaplasia and staging-specific esophageal adenocarcinoma were correlated.</p> <p>Results</p> <p>A significantly reduced E-cadherin mRNA expression could be detected in adenocarcinoma compared to dysplasia. The immunhistological activity of E-cadherin and Eph B3 was reduced in adenocarcinoma compared to dysplasia or healthy esophageal mucosa. The intracellular E-cadherin distribution changed significantly from the cytoplasm to the membrane, when the Eph receptor was simultaneously expressed. Simultaneous expression of E-cadherin and Eph B3 showed a significant inverse correlation to tumor stage.</p> <p>Conclusions</p> <p>We present novel evidence of the tumor suppressor activity of Eph B3 in esophageal adenocarcinoma possibly due to the impact on redistribution of cellular E-cadherin to the membrane. Our results suggest that this effect might play a role in the dysplasia-adenocarcinoma sequence, the infiltrative growth pattern and the development of lymph node metastases.</p> |
topic |
E-cadherin Ephrin B3 receptor Esophageal adenocarcinoma Barrett’s metaplasia |
url |
http://www.eurjmedres.com/content/17/1/10 |
work_keys_str_mv |
AT schauermatthiasc thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT stoeckleinnikolash thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT theisenjoerg thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT kropilferide thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT baldusstephan thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT hoelscherarnulf thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT feithmarkus thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT bolkeedwin thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT matuschekchristiane thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT budachwilfried thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT knoefelwolfram thesimultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT schauermatthiasc simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT stoeckleinnikolash simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT theisenjoerg simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT kropilferide simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT baldusstephan simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT hoelscherarnulf simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT feithmarkus simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT bolkeedwin simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT matuschekchristiane simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT budachwilfried simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging AT knoefelwolfram simultaneousexpressionofbothephrinb3receptorandecadherininbarrettsadenocarcinomaisassociatedwithfavorableclinicalstaging |
_version_ |
1725393223620231168 |